By Danny Sullivan – Longevity.Technology
Methuselah Foundation backs mouse study exploring epigenetic reprogramming therapy to address age-related decline in bone marrow function.
Cell rejuvenation company Turn Biotechnologies has announced the launch of a new preclinical study aimed at evaluating the effectiveness of its epigenetic reprogramming therapy in rejuvenating bone marrow stem cells. The research, conducted in collaboration with the Children’s Hospital of Philadelphia (CHOP) and supported by Methuselah Foundation, seeks to address the age-related decline in bone marrow function that impairs the body’s ability to produce disease-fighting cells, mitigate inflammation and maintain overall health.
